Clinical Trial

Developmental and Epileptic Encephalopathies Diagnosed Via Long-read Genome Sequencing

Study acronym: EEPILOG
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study focuses on children with Developmental and Epileptic Encephalopathy (DEE), a severe form of epilepsy that often has a genetic origin. Currently, standard diagnostic tools-known as short-read genome sequencing-fail to provide a diagnosis for over 50% of affected patients because they cannot detect certain complex DNA abnormalities. The purpose of this study is to evaluate the effectiveness of a newer, more advanced technology called Long-read Genome Sequencing (lrWGS). Unlike traditional methods, this technology analyzes very long fragments of DNA, allowing researchers to identify genetic errors that were previously "invisible." The study aims to answer whether Long-read Sequencing can successfully identify the genetic cause of epilepsy in patients who have already received a negative result from standard testing. By finding these missing answers, the research seeks to enable personalized medical treatments, improve genetic counseling for families, and advance our understanding of how these complex neurological conditions develop.
Trial Details
NCT Number NCT07396883
Lead Sponsor University Hospital, Strasbourg, France
Collaborators: IGBMC, Laboratoire de diagnostic génétique - NHC, Groupe Méthode en Recherche Clinique (GMRC), Bio-informatique médicale appliquée au diagnostic (UF7363) - NHC
Conditions Developmental and Epileptic Encephalopathy, Epilepsy in Children
Enrollment 20 participants
Start Date 2026-06
Primary Completion 2028-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-02-09